| Literature DB >> 29216352 |
Caitlin Lynch1, Jinghua Zhao1, Ruili Huang1, Noriko Kanaya2, Lauren Bernal2, Jui-Hua Hsieh3, Scott S Auerbach4, Kristine L Witt4, B Alex Merrick4, Shiuan Chen2, Christina T Teng4, Menghang Xia1.
Abstract
The estrogen-related receptor α (ERRα) is an orphan nuclear receptor (NR) that plays a role in energy homeostasis and controls mitochondrial oxidative respiration. Increased expression of ERRα in certain ovarian, breast, and colon cancers has a negative prognosis, indicating an important role for ERRα in cancer progression. An interaction between ERRα and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) has also recently been shown to regulate an enzyme in the β-oxidation of free fatty acids, thereby suggesting that ERRα plays an important role in obesity and type 2 diabetes. Therefore, it would be prudent to identify compounds that can act as activators of ERRα. In this study, we screened ∼10,000 (8311 unique) compounds, known as the Tox21 10K collection, to identify agonists of ERRα. We performed this screen using two stably transfected HEK 293 cell lines, one with the ERRα-reporter alone and the other with both ERRα-reporter and PGC-1α expression vectors. After the primary screening, we identified more than five agonist clusters based on compound structural similarity analysis (e.g., statins). By examining the activities of the confirmed ERRα modulators in other Tox21 NR assays, eliminating those with promiscuous NR activity, and performing follow-up assays (e.g., small interfering RNA knockdown), we identified compounds that might act as endocrine disrupters through effects on ERRα signaling. To our knowledge, this study is the first comprehensive analysis in discovering potential endocrine disrupters that affect the ERRα signaling pathway.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29216352 PMCID: PMC5774247 DOI: 10.1210/en.2017-00658
Source DB: PubMed Journal: Endocrinology ISSN: 0013-7227 Impact factor: 4.736